Loading asset research
Q3 2026 earnings · Nov 10
Metagenomi Therapeutics Inc. Common Stock
MGXNasdaq · USD · StocksQuote as of · Exchange session not verified$1.15
+1.77%
Today
MGX
Loading 1D prices…
Market cap
$43.4M
Volume
211.5K
52w high
$3.9552w low
$1.09Company profile
Metagenomi Therapeutics Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
EMERYVILLE, CA, United States
Employees
113
Fiscal year end
1231
CIK
1785279
Session & valuation
Open$1.12
Previous close$1.13
Day high$1.16
Day low$1.12
30-day avg. volume155K
Outstanding shares37.8M
Diluted EPS-$2.36
Latest annual period
P/E (trailing)-0.49
P/E (forward)-0.63
Price / book0.39
Beta0.68
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| TILInstil Bio Inc. Common Stock | $47.9M | $0.00 | — | -$10.70 | -1.59% | Hold |
| TVGNTevogen Inc. Common Stock | $49.8M | $0.00 | — | -$8.08 | +0.51% | Unrated |
| ELUTElutia Inc. Class A Common Stock | $35.9M | $12.3M | +434.23% | $0.87 | -0.36% | Buy |
| ALGSAligos Therapeutics Inc. Common Stock | $35.4M | $2.2M | -1106.72% | -$2.45 | -0.18% | Buy |
| IMAImageneBio Inc. Common Stock | $53.7M | $800K | -5668.63% | -$9.64 | -3.72% | Hold |